Načítá se...
Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The assessment of the added therapeutic value of new medicines with a new active substance is hampered by the lack of appropriate comparative information. Though the extent of this information gap is generally perceived as substantial, it has not been quanti...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Science Inc
2007
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2000577/ https://ncbi.nlm.nih.gov/pubmed/17166187 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2006.02812.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|